A Trail of CDK4 / 6 Inhibitor & MEK Inhibitor in the Treatment of

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05139082` - Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors	Phase 1/Phase 2
	Recruiting	`NCT05260385` - To Evaluate KC1036 in the Patients With Advanced Digestive System Tumors	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Not yet recruiting

NCT05139082 - Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

Phase 1/Phase 2

Recruiting

NCT05260385 - To Evaluate KC1036 in the Patients With Advanced Digestive System Tumors

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04615312
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Ning Li, PhD
Phone	13526501903
Email	lining97@126.com
Status	Recruiting
Phase	Phase 1
Start date	November 14, 2020
Completion date	August 30, 2022

A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms